Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

A retrospective chart review of pediatric patients with MS at a tertiary treatment center showed how the center’s first ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

In a study, blocking the immune system complement protein C3 was shown to reduce MS disease severity in older mice but not in ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. March is Multiple Sclerosis Awareness Month, a time to ...

Learn how early diagnosis and modern therapies can prevent Multiple Sclerosis from leading to long-term disability.